CN117122582A - Gel dressing for resisting HPV virus and preparation method thereof - Google Patents
Gel dressing for resisting HPV virus and preparation method thereof Download PDFInfo
- Publication number
- CN117122582A CN117122582A CN202310423669.0A CN202310423669A CN117122582A CN 117122582 A CN117122582 A CN 117122582A CN 202310423669 A CN202310423669 A CN 202310423669A CN 117122582 A CN117122582 A CN 117122582A
- Authority
- CN
- China
- Prior art keywords
- parts
- gel
- hpv
- phosphate
- gel dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title abstract description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000006041 probiotic Substances 0.000 claims abstract description 37
- 235000018291 probiotics Nutrition 0.000 claims abstract description 37
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 28
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 28
- 239000010452 phosphate Substances 0.000 claims abstract description 28
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 27
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 27
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 27
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 27
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 27
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 26
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 26
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 26
- 229960001631 carbomer Drugs 0.000 claims abstract description 26
- 229940041616 menthol Drugs 0.000 claims abstract description 26
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 23
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 23
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000011187 glycerol Nutrition 0.000 claims abstract description 23
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 23
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 23
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 23
- 239000008213 purified water Substances 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 14
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 229960005150 glycerol Drugs 0.000 claims abstract description 13
- 235000021317 phosphate Nutrition 0.000 claims abstract description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims abstract description 4
- 230000000529 probiotic effect Effects 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 17
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 14
- 240000003553 Leptospermum scoparium Species 0.000 claims description 14
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 9
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 abstract description 57
- 210000001215 vagina Anatomy 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 27
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000003115 biocidal effect Effects 0.000 abstract description 5
- 230000002045 lasting effect Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000035587 bioadhesion Effects 0.000 abstract description 2
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 80
- 239000000243 solution Substances 0.000 description 34
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 25
- 230000007794 irritation Effects 0.000 description 10
- 206010059313 Anogenital warts Diseases 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 241000186606 Lactobacillus gasseri Species 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 210000005000 reproductive tract Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000004392 genitalia Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 230000007227 biological adhesion Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003749 cleanliness Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108010025899 gelatin film Proteins 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/56—Lactic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
Abstract
The application provides an anti-HPV (human papillomavirus) gel dressing and a preparation method thereof, and relates to the technical field of cervical disease prevention and treatment. The preparation method comprises the following raw materials: beta-glucan, probiotics ferment, sodium hyaluronate, menthol, carbomer, glycerin, phosphate, ethylparaben, tween 80, polyvinyl alcohol and the balance of purified water. The gel has no toxic or side effect, is convenient to use, has obvious curative effect, does not contain antibiotic medicines, does not destroy normal flora of vagina, is a safe and effective HPV (human papilloma Virus) resisting medicine without side effect, has good bioadhesion force and lasting effect, is convenient for users to take medicines by themselves, has obvious curative effect on HPV patients and has good clinical application prospect. The preparation method is simple, and the gel is added according to a specific sequence, so that the gel state is uniform and stable, and simultaneously, the good treatment effect is maintained.
Description
Technical Field
The application relates to the technical field of cervical disease prevention and treatment, in particular to an anti-HPV (human papillomavirus) gel dressing and a preparation method thereof.
Background
Human papillomavirus (Human Papilloma Virus, HPV for short) is an epitheliophilic virus with a high degree of specificity. HPV is known to cause benign tumors and warts in humans, such as common warts, condyloma acuminatum, and papillomas growing on mucous membranes and skin adjacent to reproductive organs. HPV is a DNA virus, a group of viruses that can be clinically divided into many subtypes, which can lead to different diseases. HPVs can be classified into low-risk type and high-risk type according to the risks of different types of HPVs and tumorigenesis. Low-risk HPV includes HPV6, 11, 42, 43, 44, etc., and often causes benign lesions of external genital condyloma, etc., including cervical intraepithelial low level lesions (CINI). High-risk HPV types include HPV types 6, 11, 16, 18, and 6, wherein HPV types 6 and 11 frequently infect vulva, anus, vagina, etc., and HPV types 6, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, etc., are most common types of genital tract infections associated with the occurrence of cervical cancer and cervical intraepithelial high-grade lesions (CINII/III); while cervical cancer tissue specimens from countries around the world have been found to be the most common tumor caused by HPV type 16 and 18 infections.
The current treatment technology for gynecological diseases caused by HPV virus comprises the following steps: intramuscular injection, oral medicine, operation and the like, and the methods have relatively large side effects on human bodies; in addition, the drug treatment is mainly carried out through vagina, and the dosage forms of common vagina administration preparations mainly comprise suppositories, gel, effervescent tablets, vaginal tablets, lotions, capsules, films and the like, but the dosage forms have more or less defects, so that the drug action is influenced.
Disclosure of Invention
The gel dressing for resisting HPV provided by the application has the advantages of no toxic or side effect, convenience in use, obvious curative effect, no antibiotic medicine, no damage to normal flora of vagina, no side effect, safety and effectiveness, good bioadhesion, lasting effect, convenience for users to take medicine by themselves, obvious curative effect on HPV patients and good clinical application prospect.
The application also aims to provide a preparation method of the gel dressing for resisting HPV virus, which is simple, and the gel dressing is added according to a specific sequence, so that the gel state is uniform and stable, and simultaneously, the good treatment effect is maintained.
In order to solve the technical problems, the application adopts the following technical scheme:
in one aspect, the embodiment of the application provides an anti-HPV gel dressing, which comprises the following raw materials: beta-glucan, probiotics ferment, sodium hyaluronate, menthol, carbomer, glycerin, phosphate, ethylparaben, tween 80, polyvinyl alcohol and the balance of purified water.
In another aspect, an embodiment of the present application provides a method for preparing an anti-HPV gel dressing, including the steps of:
step A: adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring to obtain uniform gel solution A;
and (B) step (B): adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
step C: adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
Compared with the prior art, the embodiment of the application has at least the following advantages or beneficial effects:
the embodiment of the application provides an HPV virus-resistant gel dressing, which is formed by adding beta-glucan and sodium hyaluronate and jointly using the beta-glucan and the sodium hyaluronate on the vaginal wall to form a layer of protective gel film, so that the vaginal wall is physically isolated from outside bacteria, and the aim of reducing HPV-DNA virus load is fulfilled; the probiotics ferment produces lactic acid, adjusts the pH value of the genital tract, maintains and guides the balance of flora in the genital tract to improve the micro-environment of vagina, lightens the inflammatory reaction of vagina, reduces the abnormal secretion amount of vagina and effectively improves the cleanliness of vagina; arginine has good biocompatibility and is easy to be degraded by biological enzyme, and the rate of gel degradation is controlled by controlling the size of the crosslinking density of the hydrogel; carbomer can adsorb and wrap inactivated HPV to be discharged out of the body, accelerate rapid repair and regeneration of erosion tissues and promote healing; the cool feeling of menthol can relieve the discomfort of the vagina of a patient; the probiotic fermented product still has good activity in the acidic environment of vagina; the gel has no toxic or side effect, is convenient to use, has obvious curative effect, does not contain antibiotic medicines, does not destroy normal flora of vagina, is a safe and effective HPV (human papilloma Virus) resisting medicine without side effect, has good biological adhesion and lasting effect, and is convenient for users to take medicine by themselves.
The embodiment of the application provides a preparation method of an HPV virus-resistant gel dressing, which is simple, and the gel dressing is added according to a specific sequence, so that the gel state is uniform and stable, and meanwhile, a good treatment effect is maintained.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application more clear, the technical solutions of the embodiments of the present application will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
It should be noted that, without conflict, the embodiments of the present application and features of the embodiments may be combined with each other. The present application will be described in detail with reference to specific examples.
The embodiment of the application provides an HPV virus resistant gel dressing, which comprises the following raw materials: beta-glucan, probiotics ferment, sodium hyaluronate, menthol, carbomer, glycerin, phosphate, ethylparaben, tween 80, polyvinyl alcohol and the balance of purified water.
By adding beta-glucan and sodium hyaluronate, a layer of protective gel film is formed on the vaginal wall by combined use, so that the vaginal wall is physically isolated from external bacteria, and the aim of reducing HPV-DNA virus load is fulfilled; the probiotics ferment produces lactic acid, adjusts the pH value of the genital tract, maintains and guides the balance of flora in the genital tract to improve the micro-environment of vagina, lightens the inflammatory reaction of vagina, reduces the abnormal secretion amount of vagina and effectively improves the cleanliness of vagina; arginine has good biocompatibility and is easy to be degraded by biological enzyme, and the rate of gel degradation is controlled by controlling the size of the crosslinking density of the hydrogel; carbomer can adsorb and wrap inactivated HPV to be discharged out of the body, accelerate rapid repair and regeneration of erosion tissues and promote healing; the cool feeling of menthol can relieve the discomfort of the vagina of a patient, and the probiotics ferment still has good activity in the acidic environment of the vagina; the gel has no toxic or side effect, is convenient to use, has obvious curative effect, does not contain antibiotic medicines, does not destroy normal flora of vagina, is a safe and effective HPV (human papilloma Virus) resisting medicine without side effect, has good biological adhesion and lasting effect, and is convenient for users to take medicine by themselves.
In some embodiments of the application, the anti-HPV virus gel dressing comprises the following raw materials in parts by weight: 3-5 parts of beta-glucan, 1-2 parts of probiotic fermented product, 5-8 parts of sodium hyaluronate, 0.5-1 part of menthol, 3-5 parts of carbomer, 2-3 parts of glycerol, 0.8-1.2 parts of phosphate, 1-2 parts of ethylparaben, 1-2 parts of tween 80, 2-3 parts of polyvinyl alcohol and 60-75 parts of purified water.
In some embodiments of the application, the probiotic fermentate comprises at least one of lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus gasseri, lactobacillus plantarum.
In some embodiments of the application, the phosphate is one or more of sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate.
In some embodiments of the application, the anti-HPV virus gel dressing comprises the following raw materials in parts by weight: 5 parts of beta-glucan, 2 parts of probiotics ferment, 8 parts of sodium hyaluronate, 1 part of menthol, 5 parts of carbomer, 3 parts of glycerin, 1.2 parts of phosphate, 2 parts of ethylparaben, 2 parts of tween 80, 3 parts of polyvinyl alcohol, 0.5 part of tea tree extract, 0.6 part of kuh-seng extract and 60-75 parts of purified water.
The embodiment of the application provides a preparation method of an anti-HPV (human papillomavirus) gel dressing, which comprises the following steps:
step A: adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring to obtain uniform gel solution A;
and (B) step (B): adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
step C: adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
In some embodiments of the application, the heating temperature in step a is from 35 ℃ to 50 ℃.
In some embodiments of the application, the pH in step C ranges between 6 and 7.
The features and capabilities of the present application are described in further detail below in connection with the examples.
Example 1
The embodiment of the application provides an anti-HPV (human papillomavirus) gel dressing, and a preparation method thereof comprises the following steps:
(1) Weighing the raw materials according to the proportion: 3g of beta-glucan, 1g of probiotics ferment, 5g of sodium hyaluronate, 0.5g of menthol, 3g of carbomer, 2g of glycerin, 0.8g of phosphate, 1g of ethylparaben, 1g of tween 80, 2g of polyvinyl alcohol and 60g of purified water;
(2) Adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring, and maintaining the heating temperature at 40+ -5deg.C to obtain uniform gel solution A;
(3) Adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
(4) Adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
In this example, the phosphate salt is a mixture of sodium dihydrogen phosphate and disodium hydrogen phosphate.
In this example, the probiotic ferments include lactobacillus acidophilus and lactobacillus rhamnosus.
Example 2
The embodiment of the application provides an anti-HPV (human papillomavirus) gel dressing, and a preparation method thereof comprises the following steps:
(1) Weighing the raw materials according to the proportion: 5g of beta-glucan, 2g of probiotic fermented product, 8g of sodium hyaluronate, 1g of menthol, 5g of carbomer, 3g of glycerin, 1.2g of phosphate, 2g of ethylparaben, 2g of tween 80, 3g of polyvinyl alcohol and 75g of purified water;
(2) Adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring, and maintaining the heating temperature at 45+ -5deg.C to obtain uniform gel solution A;
(3) Adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
(4) Adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
In this example, the phosphate salt is a mixture of potassium dihydrogen phosphate and dipotassium hydrogen phosphate.
In this example, the probiotic ferments include lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus gasseri.
Example 3
The embodiment of the application provides an anti-HPV (human papillomavirus) gel dressing, and a preparation method thereof comprises the following steps:
(1) Weighing the raw materials according to the proportion: 4g of beta-glucan, 1.5g of probiotics ferment, 7g of sodium hyaluronate, 0.8g of menthol, 4g of carbomer, 2.5g of glycerin, 1g of phosphate, 1.5g of ethylparaben, 1.5g of tween 80, 2.5g of polyvinyl alcohol and 70g of purified water;
(2) Adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring, and maintaining the heating temperature at 40+ -5deg.C to obtain uniform gel solution A;
(3) Adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
(4) Adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
In this example, the phosphate is a mixture of disodium hydrogen phosphate and potassium dihydrogen phosphate.
In this example, the probiotic fermentate comprises lactobacillus rhamnosus, lactobacillus gasseri.
Example 4
The embodiment of the application provides an anti-HPV (human papillomavirus) gel dressing, and a preparation method thereof comprises the following steps:
(1) Weighing the raw materials according to the proportion: 5g of beta-glucan, 2g of probiotics ferment, 8g of sodium hyaluronate, 1g of menthol, 5g of carbomer, 3g of glycerin, 1.2g of phosphate, 2g of ethylparaben, 2g of tween 80, 3g of polyvinyl alcohol, 0.5g of tea tree extract, 0.6g of kuh-seng extract and 75g of purified water;
(2) Adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring, and maintaining the heating temperature at 45+ -5deg.C to obtain uniform gel solution A;
(3) Adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
(4) Adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
In this example, the phosphate salt is sodium dihydrogen phosphate.
In this example, the probiotic ferments include lactobacillus rhamnosus, lactobacillus gasseri, lactobacillus plantarum.
Example 5
The embodiment of the application provides an anti-HPV (human papillomavirus) gel dressing, and a preparation method thereof comprises the following steps:
(1) Weighing the raw materials according to the proportion: 5g of beta-glucan, 2g of probiotics ferment, 8g of sodium hyaluronate, 1g of menthol, 5g of carbomer, 3g of glycerin, 1.2g of phosphate, 2g of ethylparaben, 2g of tween 80, 3g of polyvinyl alcohol, 0.5g of tea tree extract, 0.6g of kuh-seng extract and 75g of purified water;
(2) Adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring, and maintaining the heating temperature at 40+ -5deg.C to obtain uniform gel solution A;
(3) Adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
(4) Adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
In this example, the phosphate is potassium dihydrogen phosphate.
In this example, the probiotic ferments include lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus gasseri, lactobacillus plantarum.
Example 6
The embodiment of the application provides an anti-HPV (human papillomavirus) gel dressing, and a preparation method thereof comprises the following steps:
(1) Weighing the raw materials according to the proportion: 4g of beta-glucan, 1.5g of probiotics ferment, 7g of sodium hyaluronate, 0.8g of menthol, 4g of carbomer, 2.5g of glycerin, 1g of phosphate, 1.5g of ethylparaben, 1.5g of tween 80, 2.5g of polyvinyl alcohol, 0.5g of tea tree extract, 0.6g of kuh-seng extract and 70g of purified water;
(2) Adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring, and maintaining the heating temperature at 45+ -5deg.C to obtain uniform gel solution A;
(3) Adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
(4) Adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
In this example, the phosphate is dipotassium hydrogen phosphate.
In this example, the probiotic fermentate comprises lactobacillus gasseri, lactobacillus plantarum.
Experimental example
(1) Security detection
Vaginal appearance irritation scoring criteria: the three of vaginal congestion, edema and secretions were scored as indicators with reference to the Eckstein evaluation criteria. The stimulation degree of each index was determined to be 0 to 4 points according to the weight, and the stimulation severity was increased with increasing score, as shown in table 2. An average of the three index scores less than 3 is divided into a smaller range of irritation. 3.75 to 6 is classified into a mild stimulation range. And 6.75 to 9 are divided into a moderate stimulation range. 9.75 to 12 parts of the weight stimulation range. A score total score in the range of 0 to 6 points indicates less or no irritation, a score in the range of 6.75 to 7.5 points indicates mild or moderate irritation, and a score equal to or greater than 8.25 points indicates severe irritation.
According to Table 1, the total vaginal irritation score was obtained by summing the vaginal congestion, edema and secretion irritation scores of each mouse, and the final vaginal irritation score was obtained by dividing the total vaginal irritation score of all mice by the number of animals. The vaginal irritation level of the test animals was determined according to the measurement and evaluation criteria shown in Table 2.
TABLE 1 vaginal irritation scoring rules
TABLE 2 stimulation evaluation criteria
| Stimulation level | Score value |
| No stimulation | 0～3 |
| Mild irritation | 3.75～6 |
| Moderate stimulation | 6.75～9 |
| Severe irritation | 9.75～12 |
Experimental results: the vaginal wall tissues of four groups of mice are not obviously damaged by naked eyes, and the total score value is in the range of 0-6 minutes, which indicates that the gel dressings prepared in examples 1-6 for resisting HPV viruses generate slight irritation to the vaginal tissues of the mice. Therefore, the gel dressing for resisting HPV virus provided by the application only generates slight irritation to the vagina of a mouse, and meets the requirement of vaginal administration.
(2) Clinical effects of HPV infection treatment
The effect of the gel dressing against HPV virus on condyloma acuminatum and HPV infected patients was observed. After removing the excrescence by physical therapy, the genital condyloma patient is internally provided with a fornix behind the vagina and smeared with the vulva. 180 patients infected with HPV are invited to be divided into 6 groups of 30 persons, the anti-HPV gel dressings prepared in examples 1 to 6 are respectively applied, and feedback results of the subjects are collected after 3 months (see Table 3).
And (3) judging curative effect: (1) and (3) healing: cervical HPV-DNA turns negative, genital condyloma acuminatum does not recur; (2) the method is effective: the cervical HPV-DNA review results are reduced; (3) invalidation: cervical HPV-DNA review did not descend or ascend and genital warts repeatedly developed.
TABLE 3 therapeutic efficacy of gel dressing against HPV virus on condyloma acuminatum and HPV infected patients
| Total number of cases | Number of recovery cases | Number of effective cases | Number of invalid cases | |
| Example 1 | 30 | 27 | 3 | 0 |
| Example 2 | 30 | 25 | 5 | 0 |
| Example 3 | 30 | 26 | 4 | 0 |
| Example 4 | 30 | 26 | 4 | 0 |
| Example 5 | 30 | 27 | 3 | 0 |
| Example 6 | 30 | 27 | 3 | 0 |
As is clear from Table 3, after one treatment course, 180 patients suffering from condyloma acuminatum and HPV infection were treated with the anti-HPV gel dressing, all of them were cured, cervical HPV-DNA was turned negative, and genital condyloma acuminatum was free from recurrence. The anti-HPV virus gel dressing prepared by the application has obvious curative effect on HPV patients and good clinical application prospect.
In summary, the embodiment of the application provides an anti-HPV gel dressing, which is formed by adding beta-glucan and sodium hyaluronate and jointly using a layer of protective gel film on the vaginal wall to form physical isolation between the vaginal wall and external bacteria, so as to achieve the purpose of reducing HPV-DNA virus load; the probiotics ferment produces lactic acid, adjusts the pH value of the genital tract, maintains and guides the balance of flora in the genital tract to improve the micro-environment of vagina, lightens the inflammatory reaction of vagina, reduces the abnormal secretion amount of vagina and effectively improves the cleanliness of vagina; arginine has good biocompatibility and is easy to be degraded by biological enzyme, and the rate of gel degradation is controlled by controlling the size of the crosslinking density of the hydrogel; carbomer can adsorb and wrap inactivated HPV to be discharged out of the body, accelerate rapid repair and regeneration of erosion tissues and promote healing; the cool feeling of menthol can relieve the discomfort of the vagina of a patient, and the probiotics ferment still has good activity in the acidic environment of the vagina; the gel has no toxic or side effect, is convenient to use, has obvious curative effect, does not contain antibiotic medicines, does not destroy normal flora of vagina, is a safe and effective HPV (human papilloma Virus) resisting medicine without side effect, has good biological adhesion and lasting effect, and is convenient for users to take medicine by themselves.
The embodiment of the application provides a preparation method of an HPV virus-resistant gel dressing, which is simple, and the gel dressing is added according to a specific sequence, so that the gel state is uniform and stable, and meanwhile, a good treatment effect is maintained.
The embodiments described above are some, but not all embodiments of the application. The detailed description of the embodiments of the application is not intended to limit the scope of the application, as claimed, but is merely representative of selected embodiments of the application. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application.
Claims (8)
1. An anti-HPV gel dressing is characterized by comprising the following raw materials: beta-glucan, probiotics ferment, sodium hyaluronate, menthol, carbomer, glycerin, phosphate, ethylparaben, tween 80, polyvinyl alcohol and the balance of purified water.
2. The anti-HPV virus gel dressing of claim 1, comprising the following raw materials in parts by weight: 3-5 parts of beta-glucan, 1-2 parts of probiotic fermented product, 5-8 parts of sodium hyaluronate, 0.5-1 part of menthol, 3-5 parts of carbomer, 2-3 parts of glycerol, 0.8-1.2 parts of phosphate, 1-2 parts of ethylparaben, 1-2 parts of tween 80, 2-3 parts of polyvinyl alcohol and 60-75 parts of purified water.
3. The HPV virus resistant gel dressing of claim 1, wherein the probiotic ferment comprises at least one of lactobacillus acidophilus, lactobacillus rhamnosus, lactobacillus grignard, lactobacillus plantarum.
4. The HPV virus resistant gel dressing of claim 1, wherein the phosphate is one or more of sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate.
5. The anti-HPV virus gel dressing of claim 1, comprising the following raw materials in parts by weight: 5 parts of beta-glucan, 2 parts of probiotics ferment, 8 parts of sodium hyaluronate, 1 part of menthol, 5 parts of carbomer, 3 parts of glycerin, 1.2 parts of phosphate, 2 parts of ethylparaben, 2 parts of tween 80, 3 parts of polyvinyl alcohol, 0.5 part of tea tree extract, 0.6 part of kuh-seng extract and 60-75 parts of purified water.
6. A method of preparing an HPV virus resistant gel dressing according to any one of claims 1 to 5, comprising the steps of:
step A: adding sodium hyaluronate, carbomer, glycerol, ethyl hydroxybenzoate, tween 80 and polyvinyl alcohol into purified water, mixing, heating while stirring to obtain uniform gel solution A;
and (B) step (B): adding beta-glucan, probiotic fermented product, menthol, tea tree extract and radix sophorae flavescentis extract into the gel solution A in sequence to obtain gel solution B;
step C: adding phosphate solution into gel B to regulate pH value, and packaging to obtain gel dressing for resisting HPV virus.
7. The method of preparing an HPV virus resistant gel dressing according to claim 6, wherein the heating temperature in step a is 35 ℃ to 50 ℃.
8. The method of claim 6, wherein the pH in step C is in the range of 6-7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310423669.0A CN117122582A (en) | 2023-04-20 | 2023-04-20 | Gel dressing for resisting HPV virus and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310423669.0A CN117122582A (en) | 2023-04-20 | 2023-04-20 | Gel dressing for resisting HPV virus and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117122582A true CN117122582A (en) | 2023-11-28 |
Family
ID=88857082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310423669.0A Pending CN117122582A (en) | 2023-04-20 | 2023-04-20 | Gel dressing for resisting HPV virus and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117122582A (en) |
-
2023
- 2023-04-20 CN CN202310423669.0A patent/CN117122582A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020147533A1 (en) | Use of separated rhodococcus ruber cell wall skeleton in preparation of medicine for treatment of herpes simplex and/or herpes zoster | |
| CN104353058B (en) | Pokeweed antiviral protein lyophilized powder complexing agent and preparation method thereof | |
| CN107961265A (en) | A kind of gynecological gel prevented and suppress HPV viruse | |
| CN115671032A (en) | Medical anti-HPV biological protein gel containing biological protein and preparation method thereof | |
| WO2020182180A1 (en) | Use of rhodococcus ruber product in treatment of vulvar white lesions | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN112315899B (en) | Biological gel dressing for preventing/treating HPV and gynecological inflammation and preparation method and application thereof | |
| CN117122582A (en) | Gel dressing for resisting HPV virus and preparation method thereof | |
| CN114903944B (en) | Composition and preparation for improving cervical HPV infection symptoms and preparation method | |
| CN114159614A (en) | anti-HPV protein dressing and preparation method thereof | |
| TW202237158A (en) | Use of rhodococcus ruber cell wall skeleton in the treatment of radiation related disease | |
| CN112546202A (en) | Complexing agent with HPV virus inhibiting function and preparation method thereof | |
| CN112402463A (en) | Compound probiotics for inhibiting vagina inflammation and product and application thereof | |
| CN111920825B (en) | anti-HPV composition for female genital tract and application thereof | |
| CN117180492B (en) | Gel dressing composition containing silk fibroin, preparation method and application | |
| EP4046646A1 (en) | Pharmaceutical composition for the treatment of hpv infections | |
| CN117618331A (en) | anti-Human Papilloma Virus (HPV) gel dressing | |
| CN113384548A (en) | Vaginal effervescent tablet with HPV (human papillomavirus) infection resistance and preparation method thereof | |
| CN106267167A (en) | A kind of lactalbumin oleic acid complex and carrageenan composition of medicine and its preparation method and application | |
| Satoh et al. | Anogenital giant condyloma in an infant with liver transplantation | |
| CN113398168A (en) | Antibacterial gel with HPV (human papillomavirus) virus inactivation effect | |
| CN115581760A (en) | Gel for preventing and treating HPV (human papillomavirus) and preparation method thereof | |
| CN114259536A (en) | Pharmaceutical formulation for treating HPV virus | |
| CN116407613A (en) | HPV-resistant gel containing lithospermum oligosaccharide peptide | |
| CA3144300A1 (en) | Prophylaxis and treatment of an infection of the cervix with human papilomavirus (hpv) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |